1887

Abstract

We recently showed that BZLF1, the gene encoding the Epstein–Barr virus (EBV) Zebra protein, was expressed in all eight nasopharyngeal carcinoma (NPC) specimens studied. We present here studies on the expression of EBV lytic cycle genes in the same eight NPC biopsies to determine if production of the ZEBRA transactivator could lead to a complete productive cycle. The tumour lesions exhibit a number of different patterns of limited lytic gene expression. In three out of eight tumours neither BRLF1 nor BMLF1 expression could be detected. Otherwise BMLF1 mRNA was expressed in all the other specimens. Three specimens also expressed BRLF1. Two specimens not only exhibited BZLF1, BMLF1 and BRLF1 transcripts, but also expressed the late gene BLLF1 which encodes the membrane protein gp220. The early gene product BBLF2 could not be detected in any of the eight NPC. However, expression of the late gene encoding the lytic truncated form of LMP1 (D1LMP) was found in seven of the eight NPC biopsies. Thus, it could be suggested that the EBV abortive lytic cycle occurred in most of the NPC studied.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-76-6-1401
1995-06-01
2022-08-11
Loading full text...

Full text loading...

/deliver/fulltext/jgv/76/6/JV0760061401.html?itemId=/content/journal/jgv/10.1099/0022-1317-76-6-1401&mimeType=html&fmt=ahah

References

  1. Baichwal V. R., Sugden B. 1989; The multiple membrane-spanning segments of the BNLF-1 oncogene from Epstein–Barr virus are required for transformation. Oncogene 4:67–74
    [Google Scholar]
  2. Bashir R., Luka J., Cheloha K., Chamberlain M., Hochberg F. 1993; Expression of Epstein–Barr virus proteins in primary CNS lymphoma m AIDS patients. Neurology 43:2358–2362
    [Google Scholar]
  3. Beisel C., Tanner J., Matsuo T., Thorley-Lawson D., Kezdy F., Kieff E. 1985; Two major outer envelope glycoproteins of Epstein–Barr virus are encoded by the same gene. Journal of Virology 54:665–674
    [Google Scholar]
  4. Bibeau F., Brousset P., Knecht H., Meggetto F., Drouet E., Rubin B., Delsol G. 1994; Epstein–Barr virus replication in Flodgkins disease. Bulletin du Cancer 81:114–118
    [Google Scholar]
  5. Brooks L., Yao Q. Y., Rickinson A. B., Young L. S. 1992; Epstein–Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. Journal of Virology 66:2689–2697
    [Google Scholar]
  6. Buisson M., Manet E., Trescol-Biemont M. C., Gruffat H., Durand B., Sergeant A. 1989; The Epstein–Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R. Journal of Virology 63:5276–5284
    [Google Scholar]
  7. Busson P., McCoy R., Sadler R., Gilligan K., Tursz T., Raab-Traub N. 1992; Consistent transcription of the Epstein–Barr virus LMP2 gene in nasopharyngeal carcinoma. Journal of Virology 66:3257–3262
    [Google Scholar]
  8. Chen C. L., Sadler R. H., Walling D. M., Su I. J., Hsieh H. C., Raab-Traub N. 1993; Epstein–Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. Journal of Virology 67:6303–6308
    [Google Scholar]
  9. Chen H. L., Lung K. M. L., Sham J. S. T., Choy D. T. K., Griffin B., Ng K. H. 1992; Transcription of BamHI-A region of the EBV genome in NPC tissues and m B cells. Virology 191:193–201
    [Google Scholar]
  10. Chirgwin J. M., Przybyla A. E., MacDonald R. J., Rutter W. J. 1979; Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294–5299
    [Google Scholar]
  11. Cochet C., Martel-Renoir D., Grunewald V., Bosq J., Cochet G., Schwaab G., Bernaudin J. F., Joab I. 1993; Expression of the Epstein–Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumour cells. Virology 197:358–365
    [Google Scholar]
  12. Corbo L., Le Roux F., Sergeant A. 1994; The EBV early gene product EB2 transforms rodent cells through a signalling pathway involving c-MYC. Oncogene 9:3299–3304
    [Google Scholar]
  13. Dambaugh T., Beosem C., Hummel M., King W., Fennewald S., Cheung A., Heller M., Raab-Traub N., Kieff E. 1980; Epstein–Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proceedings of the National Academy of Sciences, USA 77:2999–3003
    [Google Scholar]
  14. De Thé G. 1980; The role of Epstein–Barr virus in human diseases infectious mononucleosis (IM), Burkitt′s lymphomas (BL), and nasopharyngeal carcinoma (NPC). In Viral Oncology pp 769–797 Edited by Klein G. New York: Raven Press;
    [Google Scholar]
  15. Fahraeus R., Huli F., Ernberg I., Finke J., Rowe M., Klein G., Falk K., Nilsson E., Yadav M., Busson P., Turz T., Kaliing B. 1988; Expression of Epstein–Barr virus-encoded proteins in nasopharyngeal carcinoma. International Journal of Cancer 42:329–338
    [Google Scholar]
  16. Farrell P. J. 1989; Epstein–Barr virus genome. Advances in Viral Oncology 8:103–259
    [Google Scholar]
  17. Gilligan K. J., Rajadurai P., Lin J. C., Busson P., Abdel-Hamid M., Prasad U., Tursz T., Raab-Traub K. 1991; Expression of the Epstein–Barr virus Bam HI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. Journal of Virology 65:6252–6259
    [Google Scholar]
  18. Gilligan K., Sato K., Rajadurai P., Busson P., Young L., Rickinson A., Tursz T., Raab-Traub N. 1990; Novel transcription from the Epstein–Barr virus terminal Eco RI fragment, DIJhet, in a nasopharyngeal carcinoma. Journal of Virology 64:4948–4956
    [Google Scholar]
  19. Gradoville L., Grogan E., Taylor N., Miller G. 1990; Differences in the extent of activation of Epstein–Barr virus replicative gene expression among four nonproducer cell lines stably transformed by oriP/BZLFl plasmids. Virology 178:345–354
    [Google Scholar]
  20. Gutsch D. E., Holley-Guthrie E. A., Zhang Q., Stein M., Blanar M. A., Baldwin A. S., Kenney S. C. 1994; The b-Zip transactivator of Epstein–Barr virus, BZLF1, functionally and physically interacts with p65 subunit of NFkB. Molecular and Cellular Biology 14:1939–1948
    [Google Scholar]
  21. Henle W., Ho J. H. C., Henle G., Kwan M. C. 1973; Antibodies to Epstein–Barr virus related antigens in nasopharyngeal carcinoma. Comparison to active cases and long term survivors. Journal of the National Cancer Institute 51:361–369
    [Google Scholar]
  22. Hitt K. M., Allday M. J., Hara T., Karran L., Jones M. D., Busson P., Tursz T., Ernberg I., Griffin B. E. 1989; EBV gene expression in an NPC-related tumour. EMBO Journal 8:2639–2651
    [Google Scholar]
  23. Hudson G., Farrell P. J., Barrell B. G. 1985; Two related but differentially expressed potential membrane proteins encoded by the £coRI Dhet region of Epstein–Barr virus B95-8. Journal of Virology 53:528–535
    [Google Scholar]
  24. Joab I., Nicolas J. C., Schwaab G., De The G., Clausse B., Perricaudet M., Zeng Y. 1991; Detection of anti-Epstein–Barr virus transactivator, ZEBRA, antibodies in sera from patients with nasopharyngeal carcinoma. International Journal of Cancer 48:647–649
    [Google Scholar]
  25. Katz B. Z., Raab-Traub N., Miller G. 1989; Latent and replicating forms of Epstein–Barr virus DNA in lymphomas and lymphoproliferative diseases. Journal of Infectious Diseases 160:589–598
    [Google Scholar]
  26. Manet E., Gruffat H., Trescol-Biemont M. C., Moreno N., Chambard P., Giot J. F., Sergeant A. 1989; Epstein–Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators. EMBO Journal 8:1819–1826
    [Google Scholar]
  27. Martel-Renoir D., Grunewald V., Cochet C., Bosq J., Schwaab G., Bernaudin J. F., Joab I. 1993; Expression of Epstein–Barr virus transactivator, ZEBRA, in nasopharyngeal carcinoma tumour cells. In The Epstein–Barr Virus and Associated Diseases pp 489–496 Edited by Tursz T., Pagano J., Ablashi D. V. D., De Thé G., Lenoir G. Paris: John Libbey Eurotext Ltd;
    [Google Scholar]
  28. Miller G. 1990; Epstein–Barr virus. Biology, pathogenesis and medical aspects. In Virology pp 1921–1958 Edited by Fields B. N., Knipe D. M. New York: Raven Press;
    [Google Scholar]
  29. Niedobitek G., Young L. S., Sam C. K., Brooks L., Prasad U., Rickinson A. B. 1992; Expression of Epstein–Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. American Journal of Pathology 140:879–887
    [Google Scholar]
  30. Oda K., Tamaru J., Takenouchi T., Mikata A., Nunomura M., Saitoh N., Sarashina H., Nakajima N. 1993; Association of Epstein–Barr virus with gastric carcinoma with lymphoid stroma. American Journal of Pathology 143:1063–1071
    [Google Scholar]
  31. Pallesen G., Hamilton-Dutoit S. J., Rowe M., Lisse I., Ralfkiaer E., Sandvej K., Young L. S. 1991; Expression of Epstein–Barr virus replicative proteins in AIDS-related non-Hodgkin′s lymphoma cells. American Journal of Pathology 165:289–299
    [Google Scholar]
  32. Pallesen G., Sandvej K., Hamilton-Dutoit S. J., Rowe M., Young L. S. 1991; Activation of Epstein–Barr virus replication in Hodgkin and Reed-Sternberg cells. Blood 78:1162–1165
    [Google Scholar]
  33. Raab-Traub N., Hood R., Yang C. S., Henry B., Paganoj S. 1983; Epstein–Barr virus transcription in nasopharyngeal carcinoma. Journal of Virology 48:580–590
    [Google Scholar]
  34. Rowe M., Evans H. S., Young L. S., Hennessy K., Kieff E., Rickinson A. B. 1987; Monoclonal antibodies to the latent membrane protein of Epstein–Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. Journal of General Virology 68:1575–1586
    [Google Scholar]
  35. Rowlands D. C., Ito M., Mangham D. C., Reynolds G., Herbst H., Hallissey M. T., Fielding J. W. L., Newbold K. M., Jones E. L., Young L. S., Niedobitek G. 1993; Epstein–Barr virus and carcinomas - rare association of the virus with gastric adenocarcinomas. British Journal of Cancer 68:1014–1019
    [Google Scholar]
  36. Sam C. K., Brooks L. A., Niedobitek G., Young L. S., Prasad U., Rickinson A. B. 1993; Analysis of Epstein–Barr virus infection in nasopharyngeal biopsies from a group at high risk of nasopharyngeal carcinoma. International Journal of Cancer 53:957–962
    [Google Scholar]
  37. Stewart J. P., Arrand J. R. 1993; Expression of the Epstein–Barr virus latent membrane protein in nasopharyngeal carcinoma biopsy specimens see comments. Human Pathology 24:239–242
    [Google Scholar]
  38. Tosoni-Pittoni E., Joab I., Nicolas J. C., Perricaudet M. 1989; Complete characterization of the gene coding for the Epstein–Barr virus major membrane antigen gp 220/340 and selective expression of a secreted form of gp 220. Biochemical and Biophysical Research Communications 158:676–684
    [Google Scholar]
  39. Wang D., Liebowitz D., Wang F., Gregory C., Rickinson A., Larson R., Springer T., Kieff E. 1988; Epstein–Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. Journal of Virology 62:4173–4184
    [Google Scholar]
  40. Young L. S., Dawson C. W., Clark D., Rufani H., Busson P., Tursz T., Johnson A., Rickinson A. B. 1988; Epstein–Barr virus gene expression in nasopharyngeal carcinoma. Journal of General Virology 69:1051–1065
    [Google Scholar]
  41. Zhang Q., Gutsch D., Kenney S. 1994; Functional and physical interaction between p53 and BZLF1: implications for Epstein–Barr virus latency. Molecular and Cellular Biology 14:1929–1938
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-76-6-1401
Loading
/content/journal/jgv/10.1099/0022-1317-76-6-1401
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error